About Reactive Biosciences
Reactive Biosciences is a private company based in Durham, North Carolina. It has reported $43,030,290 raised in five offerings on Form D since March 2017. Its chief executive is Julie Grant.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Jun 12, 2023 | Jun 22, 2023 | $4,000,000fully sold | 10 | $400K | DebtRule 506(b) | Form D ↗ |
| Aug 5, 2021 | Sep 12, 2022 | $23,499,998of $40.0M target | 10 | $2.3M | EquityRule 506(b) | Form D ↗ |
| Dec 20, 2019 | Jan 3, 2020amended May 15, 2020 | $2,000,000fully sold | 14 | $142K | Debt, OptionsRule 506(b) | Form D/A ↗1 earlier filing |
| Feb 15, 2019 | Feb 28, 2019 | $3,000,000of $4.2M target | 14 | $214K | DebtRule 506(b) | Form D ↗ |
| Mar 1, 2017 | Mar 22, 2017 | $10,530,292fully sold | 28 | $376K | EquityRule 506(b) | Form D ↗ |
| Total, five offerings | $43,030,290 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Reactive Biosciences's Form D filed Jun 22, 2023.
Earlier filings also listed Stephen Benkovic (director, last listed May 2020), Roger Kemble (ceo and director, last listed May 2020), Rich Gianni (executive officer, last listed May 2020), Raj Kaul (director, last listed May 2020), Paul Schimmel (director, last listed May 2020), Kristina Burow (executive officer, last listed May 2020), Joel Marcus (director, last listed May 2020) and John Dombrosky (ceo/president, last listed Feb 2019).